Analytical Data
-
Gene name
PSMa6
- Application
-
Alternative Names
IOTA; PROS27; p27K; 27 kDa prosomal protein; Macropain iota chain; Proteasome iota chain; Multicatalytic endopeptidase complex iota chain
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P60900
-
Expression Region
Met1~Asp246
-
Molecular Weight
31kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PSMa6, or Proteasome Subunit Alpha 6, is a key component of the 26S proteasome, a critical enzyme complex involved in protein degradation in eukaryotic cells. Research on PSMa6 has gained significant attention due to its essential role in maintaining cellular homeostasis by regulating the degradation of misfolded or unneeded proteins, thereby influencing various cellular processes such as the cell cycle, apoptosis, and response to stress. Abnormalities in proteasome function, including alterations in PSMa6 expression or structure, have been implicated in several diseases, particularly cancer and neurodegenerative disorders. As cancer cells often exhibit altered proteasome activity to evade apoptosis and promote survival, PSMa6 has garnered interest as a potential therapeutic target. Additionally, its involvement in antigen processing and presentation makes it a candidate of interest in immunology, where manipulating its function could enhance immune responses against tumors. Consequently, studies focusing on the recombinant production of PSMa6 are vital for elucidating its structure-function relationships, developing specific inhibitors or modulators, and exploring its potential as a biomarker for disease progression. Overall, the investigation of PSMa6 recombinant protein represents a promising avenue for advancing our understanding of proteasome biology and its implications in health and disease.
